Design Therapeutics Statistics
Total Valuation
DSGN has a market cap or net worth of $204.93 million. The enterprise value is -$20.34 million.
Important Dates
The last earnings date was Wednesday, May 7, 2025, after market close.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
DSGN has 56.77 million shares outstanding. The number of shares has increased by 0.94% in one year.
| Current Share Class | 56.77M |
| Shares Outstanding | 56.77M |
| Shares Change (YoY) | +0.94% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 15.54% |
| Owned by Institutions (%) | 39.64% |
| Float | 25.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.87 |
| P/TBV Ratio | 0.91 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 28.37, with a Debt / Equity ratio of 0.01.
| Current Ratio | 28.37 |
| Quick Ratio | 28.06 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -22.59% and return on invested capital (ROIC) is -17.02%.
| Return on Equity (ROE) | -22.59% |
| Return on Assets (ROA) | -16.56% |
| Return on Invested Capital (ROIC) | -17.02% |
| Return on Capital Employed (ROCE) | -29.84% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.04M |
| Employee Count | 54 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.79% in the last 52 weeks. The beta is 1.78, so DSGN's price volatility has been higher than the market average.
| Beta (5Y) | 1.78 |
| 52-Week Price Change | -20.79% |
| 50-Day Moving Average | 4.12 |
| 200-Day Moving Average | 4.99 |
| Relative Strength Index (RSI) | 45.06 |
| Average Volume (20 Days) | 131,291 |
Short Selling Information
The latest short interest is 3.54 million, so 6.23% of the outstanding shares have been sold short.
| Short Interest | 3.54M |
| Short Previous Month | 3.47M |
| Short % of Shares Out | 6.23% |
| Short % of Float | 13.86% |
| Short Ratio (days to cover) | 22.96 |
Income Statement
| Revenue | n/a |
| Gross Profit | -49.93M |
| Operating Income | -68.40M |
| Pretax Income | -50.53M |
| Net Income | -56.20M |
| EBITDA | -67.79M |
| EBIT | -68.40M |
| Earnings Per Share (EPS) | -$0.99 |
Full Income StatementBalance Sheet
The company has $229.67 million in cash and $2.14 million in debt, giving a net cash position of $227.53 million or $4.01 per share.
| Cash & Cash Equivalents | 229.67M |
| Total Debt | 2.14M |
| Net Cash | 227.53M |
| Net Cash Per Share | $4.01 |
| Equity (Book Value) | 227.92M |
| Book Value Per Share | 4.01 |
| Working Capital | 225.41M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$47.46 million and capital expenditures -$217,000, giving a free cash flow of -$47.67 million.
| Operating Cash Flow | -47.46M |
| Capital Expenditures | -217,000 |
| Free Cash Flow | -47.67M |
| FCF Per Share | -$0.84 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |